Once-Weekly Insulin Icodec Arrives for Type 2 Diabetes

October 2026

Insulin icodec (Awiqli) will be the first once-WEEKLY U-700 insulin.

Think of it as an ultra-long-acting basal insulin.

Icodec’s half-life is about a week, mainly due to binding albumin in the bloodstream...making a “depot” that slowly releases insulin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote